指南与共识消化道肿瘤放疗姑息放疗与转移瘤

原发性肝癌外照射放疗:ASTRO临床实践指南

External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline.
指南 / 共识 · Pract Radiat Oncol · 2021-10-21

美国放射肿瘤学会(ASTRO)针对肝细胞癌(HCC)和肝内胆管癌(IHC)的外照射放疗(EBRT)适应证与技术剂量制定循证推荐。指南基于系统文献回顾和预设共识方法,覆盖根治、巩固、挽救、术前(含移植桥接)、辅助及姑息等场景,强调多学科协作。

要点

  • 不可根治的局限性HCC,EBRT可作为潜在一线治疗(强推荐)。
  • 肝导向治疗不完全缓解后可行巩固EBRT,局部复发可挽救EBRT(强推荐)。
  • 不可切除IHC应考虑巩固EBRT±化疗,通常全身治疗后进行。

核心结论

  • EBRT是HCC和IHC多场景治疗的重要选择,推荐强调多学科协作。

研究设计与样本

  • ASTRO组建工作组,基于系统文献回顾和预设共识方法及证据分级系统,回答5个关键问题。

主要发现

  • 强推荐EBRT用于不可根治的肝局限性HCC一线治疗、肝导向治疗不完全缓解后巩固及局部复发挽救。
  • 条件推荐EBRT用于肝局限性多灶或不可切除HCC或大血管侵犯,与全身或导管治疗序贯。
  • 条件推荐姑息EBRT用于有症状的原发HCC和/或大血管瘤栓。
  • 条件推荐EBRT作为移植桥接或手术前治疗,用于仔细选择的患者。
  • 不可切除IHC可考虑巩固EBRT±化疗,通常全身治疗后进行;高危特征切除后IHC条件推荐辅助EBRT。

关键数值与推荐

  • 剂量分割方案和技术选择应基于疾病范围、位置、基础肝功能和可用技术。

临床怎么用

  • 对不可根治的肝局限性HCC可考虑EBRT作为一线治疗。
  • 肝导向治疗不完全缓解后可行巩固EBRT,局部复发可挽救EBRT。
  • 不可切除IHC通常在全身治疗后考虑巩固EBRT±化疗。

局限性

  • 未来研究应进一步明确EBRT在肝导向和全身治疗背景下的作用,并优化方案和技术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This guideline provides evidence-based recommendations for the indications and technique-dose of external beam radiation therapy (EBRT) in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC). METHODS: The American Society for Radiation Oncology convened a task force to address 5 key questions focused on the indications, techniques, and outcomes of EBRT in HCC and IHC. This guideline is intended to cover the definitive, consolidative, salvage, preoperative (including bridge to transplant), and adjuvant settings as well as palliative EBRT for symptomatic primary lesions. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and system for grading evidence quality and recommendation strength. RESULTS: Strong recommendations are made for using EBRT as a potential first-line treatment in patients with liver-confined HCC who are not candidates for curative therapy, as consolidative therapy after incomplete response to liver-directed therapies, and as a salvage option for local recurrences. The guideline conditionally recommends EBRT for patients with liver-confined multifocal or unresectable HCC or those with macrovascular invasion, sequenced with systemic or catheter-based therapies. Palliative EBRT is conditionally recommended for symptomatic primary HCC and/or macrovascular tumor thrombi. EBRT is conditionally recommended as a bridge to transplant or before surgery in carefully selected patients. For patients with unresectable IHC, consolidative EBRT with or without chemotherapy should be considered, typically after systemic therapy. Adjuvant EBRT is conditionally recommended for resected IHC with high-risk features. Selection of dose-fractionation regimen and technique should be based on disease extent, disease location, underlying liver function, and available technologies. CONCLUSIONS: The task force has proposed recommendations to inform best clinical practices on the use of EBRT for HCC and IHC with strong emphasis on multidisciplinary care. Future studies should focus on further defining the role of EBRT in the context of liver-directed and systemic therapies and refining optimal regimens and techniques.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Apisarnthanarax S, Barry A, Cao M, et al. External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2021. PMID: 34688956. doi:10.1016/j.prro.2021.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。